果酱视频

Bayer AG has officially opened a $44 million expansion at its manufacturing site in Myerstown, Pennsylvania. The new 70,000-square-foot annex enhances Bayer鈥檚 Consumer Health production capabilities, reinforcing the company鈥檚 commitment to delivering trusted self-care solutions throughout North America.

The expansion follows a major investment announced in 2022 and underscores Bayer鈥檚 broader strategy to support long-term growth in the region. The Myerstown facility, which has operated for over 75 years, is now the largest manufacturing site in Bayer鈥檚 global Consumer Health network. It produces iconic brands such as Bayer Aspirin, Aleve, Claritin, One A Day, Alka-Seltzer Plus, and Midol.

鈥淥ur trusted brands have supported healthy living for generations,鈥� said Dave Tomasi, president of Bayer鈥檚 Consumer Health division in North America. 鈥淭his annex allows us to bring our science-backed products to market faster and more reliably. It鈥檚 a critical step in advancing our commitment to safe, effective and high-quality self-care solutions.鈥�

The ribbon-cutting event brought together Bayer leadership, employees, elected officials, and community members to celebrate the milestone. The new addition features eight advanced product packaging lines and modernized logistics systems, designed to improve efficiency and responsiveness to evolving consumer needs.

In addition to physical upgrades, Bayer is investing in workforce development. The company is focused on equipping employees with digital skills necessary for success in modern manufacturing. It also plans to engage with local educators by hosting tours of the facility, aiming to share insights and promote STEM education in local school districts.

鈥淲e believe our people are the foundation of our growth,鈥� said Divakar Amin, vice president and site manager of the Myerstown facility. 鈥淏y upskilling our workforce and creating new opportunities, we鈥檙e helping build a vibrant future for both Bayer and the local community.鈥�

This investment in Myerstown follows the completion of Bayer鈥檚 first Cell Therapy Launch Facility in Berkeley, California, in 2023, further demonstrating the company鈥檚 strategic focus on strengthening its presence in North America.

鈥淥ur mission of 鈥楬ealth for all, Hunger for none鈥� guides everything we do,鈥� said Michael Sullivan, senior vice president of product supply for Bayer鈥檚 Consumer Health division in North America. 鈥淭his expansion represents not just a commitment to innovation and quality, but to ensuring more people have access to the health solutions they need.鈥�

With its blend of cutting-edge technology, workforce development and community engagement, Bayer鈥檚 Myerstown expansion positions the company to meet growing demand while continuing to support local economic growth.